Two cases of lymphoid malignancy involving the breast are herein presented. Both patients were admitted with a palpable breast mass. Ultrasound demonstrated hypoechoic, ill-defined lesions of the breast in both patients; mammogram also showed spiculated breast densities. Both patients underwent core biopsy, which revealed lymphomatous cells. Total-body evaluation was also performed by computed tomography and positron emission tomography/computed tomography revealing no other fluorodeoxyglucose-avid foci in the first case and supra and subdiaphragmatic disease in the second one.
(SUVmax 22) localized at the upper quadrants of the left breast. Other areas of pathologic FDG uptake were noticed in a paracaval node and in several multiple mesenteric nodes [Fig 7] . The patient is currently under a second line chemotherapy with ifosfamide gemcitabine, vinorelbine, and prednisone [IGEV] in order to undergo bone marrow transplant.
No distinct mammographic or ultrasonographic features have been described in literature to differentiate breast lymphoma from breast carcinoma. Imaging characteristics on mammography or ultrasonography are also nonspecific and indistinguishable from invasive ductal or lobular carcinoma. A sarcomatous mass and fibromatosis are also in the differential and cannot be readily distinguished from lymphoma. Fat necrosis is distinguished by showing fat signal centrally within the lesion (Table 2 ). Definitive diagnosis is made with core biopsy allowing treatment planning. Positron emission tomography/computed tomography with F-18 flourodeoxyglucose has gained value in diagnosis and monitoring therapeutic response of many cancers, including lymphoma. Breast lymphoma (Table 1) defined as lymphoma involving the breast has been historically classified into primary breast lymphoma [PBL] and secondary breast lymphoma [SBL] , including respectively 0.04% to 0.5% of malignant breast neoplasms [1] . In 1972, Wiseman and Liao [2] first proposed criteria for PBL as follows: a) adequate pathologic specimens; b) mammary tissue and lymphomatous infiltrate in close association; c) no prior diagnosis of an extramammary lymphoma and d) no evidence of concurrent widespread disease except ipsilateral axillary lymph nodes. All those patients not meeting these four criteria are considered to have SBL. And, according to these criteria, all patients with PBL have localized disease with or without regional lymph node involvement [2] . PBL represents 1% of all nonHodgkin's lymphomas NHL [3] , that is known to include a broad variety of histologic types. The majority are B-cell lymphomas, and the most common type is diffuse large B-cell lymphoma, 40% to 70%; T-cell neoplasms are rare [4] . MALT-type lymphoma (extranodal marginal zone lymphoma of Mucosa-Associated Lymphoid Tissue) is a distinct subgroup of primary lymphoma of the breast with a reported incidence between 0% and 44% according to the series reported, and is characterized by indolent behaviour and good prognosis [4, 5] . Burkitt's lymphoma, peripheral T-cell lymphoma, classical Hodgkin's lymphoma, and follicular lymphoma are less commonly noticed [4-6]. Burkitt's or Burkitt-like lymphoma, that involves the breast of a young pregnant or lactating woman, typically behaves aggressively. SBL may display a similar histological behavior with an increased frequency of follicular subtype lymphoma, though prognosis is still influenced by the primary lymphoma stage [7] [8] [9] [10] [11] . Prognosis of patients with breast lymphoma can range from 26 to 66% 5-years survival rates [12] , with diffuse large B-cell type breast lymphoma displaying the worst prognosis. Also, the latter has a significant risk of contralateral breast involvement (5%) [13] . The Extra Nodal Lymphoma Study Group, ENLSG, also noted that young age and stage IIE disease are associated with poorer prognoses. Herein we report 2 cases of patients with palpable breast lesions, confirmed by mammography (Mx), ultrasonography (US) and CT, and then staged with F-18 FDG PET/CT. Mammary lumps, at first presentation, show ( The patients underwent four cycles of chemotherapy and were followed by PET/CT to evaluate response to treatment. Breast lymphoma treatment includes systemic chemotherapy (in most cases R-CHOP) [12] [13] [14] [15] , and local radiation therapy, because of their high chemo-and radio-sensitivity [16] [17] [18] . Kim et al. [18] reported that a short course of chemotherapy followed by local radiation therapy was a safe approach for stage IAE disease. On the other hand, a combination of fullcourse chemotherapy and local radiation therapy, or even bone marrow transplant, [16] [17] [18] has to be considered for stage IIAE disease and recurrent disease, respectively.
Correct histologic characterization of a suspect breast lesion is important, as diagnostic and therapeutic approach may change significantly. Lymphoma of the breast is rare, but has to be considered in the differential diagnosis when a breast mass is seen. The presented case highlights how PET-CT correctly staged and restaged an oncologic disease, influencing the therapeutic scheme. Other areas of pathologic FDG uptake were noticed in a paracaval node and in several multiple mesenteric nodes, better seen respectively in the axial CT and PET/CT fuse images (b-c) (white arrows). PROTOCOL: The PET/CT system Discovery ST16, (GE Medical Systems, TN, USA) was used. A low dose CT scan was acquired for attenuation correction of PET images [80 mAs, 140 kVp, field of view (FOV) about 420-500mm, CT slice thickness 3.75]. After nonenhanced CT, total-body PET examination in the caudocranial direction, from upper thighs to vertex, was performed (two bed positions, 4 min per bed). Images were reconstructed using a standard iterative algorithm [ordered subsets expectation maximisation (OSEM)] after 25-30 min of acquisition. Contrast-enhanced CT scan [120-140 kVp, automatic milliamperage (limit 330-350mA), thickness 3.750 mm (reconstructed at 1.25 mm), acquisition mode 27.50/1.375:1, gantry rotation time 0.6 s, large FOV, matrix 512×512] was carried out with i.v. administration of nonionic iodinated contrast material (100-120 ml, 370 mgI/ml, at 2-2.5 ml/s).
